Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Study Summary

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Conditions

Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer

Interventions / Drugs

Mirvetuximab soravtansine plus Bevacizumab Bevacizumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment520 participants

Primary Completion—

Lead SponsorAbbVie

Data Retrieved2026-04-11 02:51:51.325470+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.